AustralianSuper Pty Ltd Sells 660,473 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

AustralianSuper Pty Ltd lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 7.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,562,222 shares of the company's stock after selling 660,473 shares during the quarter. AustralianSuper Pty Ltd owned about 0.76% of Teva Pharmaceutical Industries worth $131,601,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after purchasing an additional 22,044,407 shares in the last quarter. FMR LLC lifted its position in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC lifted its position in shares of Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Teva Pharmaceutical Industries by 472.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after buying an additional 5,186,592 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Teva Pharmaceutical Industries by 416.0% during the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after buying an additional 4,824,247 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Friday. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective on the stock. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and an average price target of $24.71.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.23 on Monday, hitting $16.29. The company's stock had a trading volume of 5,380,083 shares, compared to its average volume of 10,318,334. The company has a market capitalization of $18.68 billion, a PE ratio of -14.18, a PEG ratio of 0.94 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock's 50 day moving average is $17.01 and its 200-day moving average is $16.91.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same period in the prior year, the company earned $0.48 earnings per share. The company's quarterly revenue was up 1.9% on a year-over-year basis. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.